vTv Therapeutics Inc. (VTVT) is a late-stage biopharmaceutical company headquartered in High Point, North Carolina, developing oral small-molecule drug candidates for diabetes and other chronic diseases. Its stock price target, as calculated here, reflects eight individually verified analyst price targets, not a headline consensus figure.
The targets reviewed are: H.C. Wainwright at $42, Evercore ISI at $44, Alliance Global Partners at $55, BTIG at $57, Roth MKM at $58, LifeSci Capital at $60, and TD Cowen and Rodman & Renshaw at $67 each. Their arithmetic mean is about $56.25, rounded to a central target of $56, with a low-to-high range of $42 to $67. Every firm rates the stock Buy or Outperform, though the wide range shows genuine disagreement about how to value a pre-revenue, single-asset company.
The most recent actions include BTIG and Roth MKM maintaining Buy ratings in October 2026, LifeSci Capital reiterating at $60, and H.C. Wainwright trimming its target from $45 to $42. Bullish targets such as TD Cowen's $67 emphasize favorable risk-reward ahead of Phase 3 data, while more cautious targets reflect the company's lack of approved products and its dependence on a single binary outcome.
Shares of VTVT traded near $21 in early November 2026, toward the lower end of a 52-week range of roughly $20.56 to $44.00. Reaching the $56 central target would require a rise of about 167% from that level — a very large move that would effectively require investors to assign substantial, sustained value to cadisegliatin before its pivotal data are even reported.
The path toward the target runs through the Phase 3 CATT1 study, which completed enrollment in October 2026 with 166 patients randomized. The trial is evaluating cadisegliatin, a potential first-in-class oral, liver-selective glucokinase activator, as an adjunct to insulin in type 1 diabetes. Topline results are expected in mid-2027, and the company reported third-quarter 2026 results in November with a narrower-than-expected loss.
Cadisegliatin has received Breakthrough Therapy designation from the U.S. Food and Drug Administration, a status that can support more intensive regulatory interaction during development. The company argues that an oral adjunct to insulin addressing hypoglycemia could meet a significant unmet need in a market it estimates at roughly 9.5 million people worldwide with type 1 diabetes.
Financially, vTv Therapeutics held roughly $80 million in cash and equivalents with no debt as of its recent reports, a runway management says extends well past the anticipated CATT1 readout. A 2026 licensing payment related to its HPP737 program also strengthened the balance sheet. Positive analyst revisions and any encouraging interim or secondary data could further support the stock forecast.
The dominant risk is clinical: if the Phase 3 CATT1 trial fails to show a meaningful reduction in hypoglycemia without worsening glycemic control, the investment thesis could deteriorate sharply. Cadisegliatin remains investigational, and enrollment completion does not indicate trial success, approval, or commercial viability.
The company has no product revenue; its reported revenue has largely stemmed from one-time licensing fees rather than recurring sales. With no intermediate catalysts expected before the mid-2027 readout, shares could face valuation compression, potential future dilution to fund operations, and continued volatility characteristic of micro-cap biotechs.
VTVT trades near its 52-week low, having declined from a 52-week high near $44. The area around $20–$21 represents a meaningful support level given the recent lows, while the prior high near $44 stands as a notable resistance level far below the $56 target. The stock's 200-day average has been well above the current price, reflecting a persistent downtrend in the average analyst price target's context of a declining share price.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may vary, and none has published a formal timing commitment. The decisive event is the cadisegliatin Phase 3 CATT1 topline readout expected in mid-2027, which falls outside a typical 12-month window — a key reason investors should treat the $56 target as a directional view rather than a near-term prediction.
Investors should monitor enrollment-completion confirmations, secondary-endpoint disclosures, analyst target changes and rating actions, quarterly cash balances and share counts, and any regulatory or partnering developments. Because the thesis is event-driven, the readout itself, not interim price action, is the central catalyst.
AI Daily Buy/Sell Signals from Tickeron use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like VTVT, such signals can help traders track momentum shifts, monitor positions, and spot changing trends more efficiently than manual screening alone. Traders can use the tool to discover opportunities and stay alert to signals as conditions evolve.
Can vTv Therapeutics (VTVT) reach $56? The question ultimately rests on a single, still-unreported clinical result. The $56 central target is the average of eight Buy-rated analyst price targets spanning $42 to $67, implying a very large move of roughly 167% from the current share price near $21. Supports include Breakthrough Therapy designation, a fully enrolled pivotal trial, and a debt-free balance sheet funding the company through the data readout. The principal obstacles are binary trial risk, no product revenue, and a catalyst timeline that extends to mid-2027. Investors should treat the target as a probabilistic view of clinical success rather than a near-term forecast, and should monitor the cadisegliatin Phase 3 readout and analyst revisions above all else.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VTVT has been loosely correlated with VANI. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if VTVT jumps, then VANI could also see price increases.
| Ticker / NAME | Correlation To VTVT | 1D Price Change % | ||
|---|---|---|---|---|
| VTVT | 100% | -0.85% | ||
| VANI - VTVT | 59% Loosely correlated | +2.22% | ||
| CORT - VTVT | 49% Loosely correlated | -2.23% | ||
| NKTX - VTVT | 35% Loosely correlated | -15.09% | ||
| IMTX - VTVT | 34% Loosely correlated | -0.16% | ||
| CMND - VTVT | 34% Loosely correlated | -1.10% | ||
More | ||||